Streetbeat News

Regulatory

VTGN

Vistagen Therapeutics (NASDAQ: VTGN) is set to receive a patent from the European Patent Office for AV-101, a treatment for neuropathic pain. Preclinical studies show AV-101 has effects similar to gabapentin but with fewer side effects. Phase 1 clinical trials indicate AV-101 is well-tolerated with no significant adverse events compared to placebo. The patent will extend until at least 2034, enhancing Vistagen's global patent portfolio. The company is seeking strategic collaborations to advance AV-101's clinical development and commercialization. The FDA has granted Fast Track designation for AV-101 as a non-opioid treatment for neuropathic pain.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:30 pm

PWUPU

Trading for PWUPU was halted and then resumed at 8:30 AM ET, with updated status including news and resumption times.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:30 pm

IOVA

Iovance Biotherapeutics' stock is trading lower following the FDA's clinical hold on the IOV-LUN-202 trial due to a Grade 5 adverse event potentially related to the trial's pre-conditioning regimen.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:25 pm

PWUP

Trading for PWUP was halted and then resumed at 8:25 AM ET, with an update on news and resumption times.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:25 pm

ENVB

Enveric Biosciences has reported progress on the preclinical development of its lead prodrug candidate, EB-373, as of year-end. The company anticipates completing all preclinical activities for EB-373 by Q1 of 2024, setting the stage for a first-in-human clinical trial.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:06 pm

NKGN

NKGen Biotech has received a No Objection Letter from Health Canada for a Phase 1/2A clinical trial of SNK01, a natural killer cell therapy for moderate Alzheimer's disease. The first interim data from the trial is expected in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:03 pm

PWUPU

Trading for PWUPU was halted at 7:55 a.m. ET due to pending news. The halt is in place to manage market orderliness and investor protection pending the release of material news.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 12:55 pm

PWUP

Trading for PWUP has been halted at 7:55 a.m. ET due to pending news. The halt is in place to manage market orderliness and investor protection pending the release of material news.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 12:55 pm

PWUPW

Trading on the stock PWUPW has been halted at 7:55 a.m. ET due to pending news. The halt is in place to manage market orderliness and investor protection pending the release of material news.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 12:55 pm

BYDDF

Chinese electric vehicle company BYD (OTC:BYDDF), backed by Warren Buffett, has received a conditional license for level 3 autonomous driving tests on high-speed roads. This is the second such license BYD has obtained, with the first one received in China in July. The company has recently achieved significant milestones, including producing 6 million new energy vehicles and launching the electric SUV Song L, which competes with Tesla's Model Y. BYD's advancements position it as a strong competitor to Tesla in the global electric vehicle market.

Portfolio Pulse from Benzinga Neuro

December 27, 2023 | 12:46 pm